PREDILIFE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.55 EUR | 0.00% |
|
-11.90% | -2.63% |
| 2023 | Predilife: a project accredited by Finance Innovation | CF |
| 2023 | Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 289K 309K 24.4M | Sales 2023 * | - | Capitalization | 20.54M 22.03M 1.74B |
|---|---|---|---|---|---|
| Net income 2022 * | - | Net income 2023 * | - | EV / Sales 2022 | 79.4 x |
| Net cash position 2022 | 3.52M 3.78M 298M | Net cash position 2023 * | - 0 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 92.59% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | -11.90% | ||
| Current month | -17.16% | ||
| 1 month | -21.28% | ||
| 3 months | +28.47% | ||
| 6 months | -5.93% | ||
| Current year | -2.63% |
1 week
5.20
6.30
1 month
5.207.20
Current year
3.6024.00
1 year
3.6024.00
3 years
3.6024.00
5 years
3.6024.00
10 years
3.6024.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 31/12/03 |
Émilien Gauthier
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/06 |
Marion Renelier
LAW | General Counsel | - | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Vilgrain
BRD | Director/Board Member | 44 | 31/12/17 |
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 31/12/03 |
Antoine Bricard
BRD | Director/Board Member | 56 | 31/12/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 5.55 | 0.00% | 1 499 |
| 19/06/24 | 5.55 | -5.93% | 2,850 |
| 18/06/24 | 5.9 | +5.36% | 1,281 |
| 17/06/24 | 5.6 | -11.11% | 3,886 |
| 14/06/24 | 6.3 | 0.00% | 265 |
Real-time Euronext Paris, June 20, 2024 at 12:56 pm
More quotes
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.63% | 22.06M | |
| -43.34% | 7.74B | |
| +10.68% | 3.66B | |
| -1.60% | 2.24B | |
| -22.96% | 1.94B | |
| -22.17% | 1.64B | |
| +5.19% | 915M | |
| +17.25% | 734M | |
| -6.99% | 711M | |
| -37.14% | 454M |
- Stock Market
- Equities
- ALPRE Stock
